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Drug treatment strategies that interfere with adipokines secreted by adipose tissue, such as adiponectin and leptin, have been 
recently developed for treating obesity. Adiponectin is able of reducing both, food intake and body weight through both,  its action 
on the hypothalamus, and concerted actions on glucose and insulin sensitivity, and oxidation of fatty acids in peripheral tissues. 
Furthermore, in vitro studies have shown that adiponectin attenuates inflammation in endothelial, muscle and macrophage cells. 
Leptin acts synergistically with adiponectin in the regulation of energy balance, inhibiting food intake, and being its levels 
regulated in the hypothalamus through the endocannabinoid system and the peptides NPY/AgRP, POMC and orexins. 
Therefore, the restoration of normal adiponectin levels can be considered a good clinical option for the treatment of obesity. 
Recently, a new thiazole-derived drug called NP-1 has been described as an adiponectin promoter activator able to promote 
adiponectin release.  
We investigated the effects of NP-1 in the hypothalamus of lean (fa/-) and obese (fa/fa) leptin signaling deficient Zucker rats, 
after a 15-day exposure to vehicle or NP-1 (5 mg/Kg). Brains were removed and frozen and the hypothalamus was dissected 
out from a coronal section, following the rodent atlas of Paxinos. Protein extraction was performed from the obtained tissue to 
analyze it by Western Blot, and RNA was isolated to determine gene expression by RT-qPCR. 
Treatment with NP-1 increased circulating TNFα, which led to weight loss through decreased intake. NP-1 reduced the 
expression of adiponectin and TNF α receptors in the hypothalamus. It also reduced mRNA expression of intake promoters such 
as NPY, AGRP and hypocretin-1, and a specific obesity-dependent modulation of POMC. Leptin deficiency-induced obesity was 
associated with specific insulin resistance preventing NP-1-induced sensitization of insulin signaling (Phosphorylation of IRS1 
and PI3K) in lean animals. Finally, NP-1 was able to decrease ERK1/ERk2 and NFkB activation, suggesting reduced 
inflammation of the hypothalamus. In conclusión, NP-1 modulates feeding through increased TNFα and regulation of 
hypothalamic neuropeptides without increasing inflammation. 
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